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GRISWOLD, THE FDA, AND THE STATE LEGISLATOR:
THE REGULATION OF MIFEPREX
Mifeprex is the brand name for mifepristone, also known as
RU-486, or the French abortion pill.' On September 28, 2000, the
Food and Drug Administration ("FDA") approved the use of
Mifeprex for "the medical termination of intrauterine pregnancy
through 49 days' pregnancy."2 "Mifeprex is the first [FDA] ap-
proved early option pill providing women with a safe and effective
non-surgical option for ending early pregnancy. "'
This Note will first present background information on
Mifeprex, including how the drug works as an abortifacient,
possible side effects of the drug, other uses of the drug, and a brief
history of the drug's FDA approval and arrival into the US market.
This Note will then provide a brief summary of the current legal
standards under which abortion law and regulation is evaluated.
Finally, this Note will address several questions brought about by
the approval of Mifeprex. First, how will this drug, with its unique
ability to act as both a contraceptive and abortifacient, affect the
current abortion debate? Second, how will current state legislation
on surgical abortion cover Mifeprex medical abortion? Third, how
will Mifeprex's status as a drug affect possible state legislation,
especially in relation to distribution and availability? And finally,
how will the inherent differences between surgical abortion and the
non-invasive4 Milefrex procedure effect challenges to old abortion
laws? This Note will conclude that Mifeprex is certainly a horse of
a different color that will have a profound effect on the abortion
debate. The legislation regarding this drug will be varied.
Regulation will range from state laws specifically addressing non-
surgical abortions to federal laws regarding only the administration
of Mifeprex.
1. The name RU-486 comes from the original French manufacturer Roussel-Uclafs
36,486 product. Andrd Ulmann et al., RU 486, 262 SCI. AM. 42 (1990).
2. FDA Approval Letter, MIFEPREX (Mifepristone) Tablets, available at
http'//www.fda.gov/eder/foil/appletter/2000 /20687appltr.htm (last visited Mar. 1, 2002).
3. Mifeprex: Frequently Asked User Questions, available at httpj/earlyoptionpill.com
(last visited Mar. 1, 2002).
4. See id.
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BACKGROUND
The Drug - How it Works
Mifeprex blocks progesterone, a hormone that prepares the
lining of the uterus for the implantation of a fertilized egg.5 Once
the drug blocks progesterone, "the uterine lining softens, breaks
down and bleeding begins."' The lining also begins to secrete
prostaglandin, which causes the uterus to contract and expel the
egg.
7
In order to induce the equivalent of a miscarriage, a patient
must ingest six hundred milligrams of Mifeprex in the first of three
doctor's visits.' Two days later, the patient will take four hundred
micrograms of a second drug, misoprostol.9 Misoprostol, a drug
previously approved by the FDA for the prevention of ulcers,10 is a
prostaglandin used to supplement the prostaglandin naturally
produced by the uterine lining.1' This second drug helps complete
the expulsion process. 2 Finally, the patient visits a third time
approximately twelve days following the second visit to ascertain
that the pregnancy has been successfully terminated. 3
Side Effects and Administrator Requirements
Mifeprex does have possible side effects, which are thoroughly
detailed on the FDA-approved labeling. 4 Women who have
confirmed or suspected tubal pregnancies, intrauterine devices
(IUDs) in place, adrenal gland failure, current long-tern
corticosteroid therapy, allergies to the medication, or bleeding
disorders should not use Mifeprex."5 Additionally, potential
candidates are warned that in one out of every one hundred women
5. Id.
6. Id.
7. Robin Herman, The Politics of the Abortion Pill, WASH. POST, Oct. 3, 1989, at Health
12; Ulmann et al., supra note 1, at 42.
8. FDA News Release (Sept. 28,2000), available at http://www.fda.gov/bbs/topics/NEWS/
NEW00737.html (last visited Mar. 1, 2002).
9. Id.
10. Id.
11. See Mifeprex: Frequently Asked User Questions, supra note 3.
12. Id.
13. Id.
14. FDA New Release, supra note 8; Mifeprex: Frequently Asked User Questions, supra
note 3.
15. FDA Approves Mifepristone for the Termination of Early Pregnancy, WASH. POST,
Sept. 28, 2000, available at http'//www.washingtonpost.com/ (last visited Nov. 15, 2000).
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"bleeding can be so heavy that it requires a surgical procedure
(curettage) to stop it."16
Due primarily to these risks, the FDA and federal law require
that physicians who administer the drug have the ability to assess
the duration of pregnancy accurately, diagnose ectopic pregnancies,
and "provide surgical intervention in cases of incomplete abortions
or severe bleeding, or have made plans to provide such care through
other[s]."17 Each patient must be provided with a patient agree-
ment and medical guide, 8 and the administering physician must
give her the opportunity to read the materials and ask questions. 9
The doctor must obtain a signed patient agreement from each
patient receiving Mifeprex.2°
Quick Comparison with Surgical Abortions
The FDA has approved Mifepristone for "the termination of
early pregnancy, defined as 49 days or less, counting from the
beginning of the last menstrual period."2 ' The combination of
Mifepristone and misoprostol is ninety-six percent effective in
terminating pregnancies, as opposed to the ninety-seven percent
effectiveness of surgical abortions.22 Risks associated with surgical
abortions vary greatly from the possible- risks described above.23
Risks typically associated with surgical abortions such as injuries
to the cervix or uterus, infections, and complications from
anesthesia are avoided through the use of Mifepristone.24
The costs of the two procedures are expected to be very similar
due to the number of times women who choose the Mifepristone
option are required to visit their doctor under the FDA approval.2"
Additionally, the use of Mifepristone is more time-consuming; the
16. Center for Drug Evaluation and Research, Mifepristone Medication Guide, available
at http.//www.fda.gov/cder/drug/infopage/mifepristone/medguide.htm (last visited Aug. 8,
2002).
17. FDA Approval Letter, supra note 2.
18. Mifepristone Medication Guide, supra note 16.
19. Id.
20. Id.
21. FDA News Release, supra note 8.
22. See Ulmann et al., supra note 1, at 47. Because the pill's efficiency begins to drop
after forty-nine days, the FDA has approved it for use only within this period and has
required that doctors who prescribe the pill have experience in dating a pregnancy. Feds
Approve RU-486, Sept. 29, 2000, available at httpd/usnews.about.comlnewsissues/
usnews/library/weekly/aa092800a.htm (last visited Nov. 15, 2000).
23. Leonard A. Cole, The End of the Abortion Debate, U. PA. L. REV. 217, 217 (1989).
24. Id.
25. Id.
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procedure occurs over days rather than hours, and requires more
recuperation time.26
Alternative Uses for Mifepristone (That Blur the Line)27
Mifepristone also has the potential for working as an effective
postcoital contraceptive." When the drug is taken prior to the
implantation of a fertilized egg, as what has typically become
known as a"morning after pill"29 studies have shown that it is more
effective than alternatives (approved for use in the United States)
which use high doses of estrogen and progestogen to induce
shedding of the uterine lining and prevent implantation.0 Benefits
to women who use Mifepristone in this way also include a one dose
administration as opposed to several doses required by other
"morning after pills."3 Additionally, side effects associated with
hormone based alternatives, such as nausea and vomiting, are not
as frequent or intense in women who took Mifepristone.32
Although complete studies have not been performed,
Mifepristone has also been shown to work as an alternative to daily
birth control pills.33 Benefits to such use might include fewer side
26. Id.
27. Introduced in this section are uses for Mifepristone that tend to blur the difference
between contraception and abortion. Because the drug can potentially be used along a
continuum, to prevent fertilization, to prevent implantation, and to cause a fertilized egg's
expulsion from the lining after implantation, it questions the lines between these uses and
the current legal standards employed to protect rights. See infra notes 62-79 and
accompanying text. Additionally, current FDA regulation regarding "off-label use" of
prescription drugs may allow doctors to prescribe Mifeprex for these other uses without
express approval by the FDA. See infra notes 112-20 and accompanying text.
28. Not included in this discussion are several uses for the drug that do not have
reproductive control applications. It is interesting to note, however, that Mifepristone can
be used to induce labor and lactation, treat tumors such as breast cancer and meningioma,
and some studies have show that it may prove a viable treatment for skin wounds and
Cushing's Syndrome. See Etienne-Emile Baulieu, Contragestion and Other Clinical
Applications of RU-486, an Antiprogesterone at the Receptor, 245 SCIENCE 1351, 1355-56
(1989) (discussing uses of RU-486 in treating cancer); Ulmann et al., supra note 1, at 48
(stating that RU-486 triggers lactation in monkeys); Jeremy Cherfas & Joseph Palca,
Hormone Antagonist with Broad Potential, 245 SCIENCE 1322 (1989) (discussing research on
non-abortifacient applications of RU-486).
29. Anna Glasier et al., Mifepristone (RU 486) Compared with High-Dose Estrogen and
Progestogen for Emergency Postcoital Contraception, 327 NEw ENG. J. MED. 1041, 1041-44
(1992) (discussing how RU-486 prevents implantation of a fertilized egg).
30. Id.
31. Id.
32. Id. at 1042-43.
33. Cherfas & Palca, supra note 28, at 1322 (discussing the use of RU-486 as an
alternative to hormone using birth control pills).
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effects than hormone alternatives, fewer pills to remember,34 and
an alternative for women who cannot take estrogen or progestogen
and therefore cannot tolerate birth control pills currently on the
market.35
The History of the Drug in the United States
A brief overview of the history of the development of
Mifepristone, and of the difficulties faced by those interested in the
drug's availability in the United States, offers foreshadowing of
some of the possible legislation that might be enacted to Curtail its
availability and use. Mifepristone has been available in markets
outside of the United States since the 1980s.36 The drug was first
synthesized by Dr. Etienn-Emile Baulieu, a French scientist, in
1980."7 A few years later, Baulieu and his colleagues combined the
drug with a dose of prostaglandin to increase uterine contractions
and promote the expulsion of the fertilized egg.38 France began
trials in 1982 and RU-486 became available in October of 1988
"after the French Minister of Health declares RU486 'the moral
property of women' and orders Roussel Uclaf to return RU486 to the
market following the company's decision to withdraw the drug in
the wake of anti-abortion pressure."39 China began trials in 1983,
the United Kingdom in 1991, and Sweden in 1992.40 By 1999,
Mifepristone had been approved in Switzerland, Austria, Belgium,
Denmark, Spain, Finland, Greece, Germany, Israel, the
Netherlands, Sweden, and the United Kingdom.4
34. Mifepristone would only be taken for three days each cycle rather than every day.
Id. at 1332.
35. David P. Hamilton,RU486: More than an Abortion Pill, TECH. REV., May-June 1990,
at 18.
36. See Claude J. Aguillaume & Louise B. Tyrer, Current Status and Future Projections
on Use ofRU-486, CONTEMP. OB/GYN, June 1995, at 23, 24.
37. Ulmann et al., supra note 1, at 44.
38. Id.
39. The Fight to Make Mifepristone Ru-486 Available to U.S. Women: A Chronology in
Brief, available at httpj/www.feminist.org/gateway/ru486two.html (1996) (last visited Mar.
1, 2002) (providing a timeline of events on the way to Mifeprex approval) [hereinafter
Chronology].
40. Mifepristone: A Brief History, available at http'//www.plannedparenthood.org/
library/ABORTION/ Mifepristone.html (last visited Mar. 1, 2002).
41. Sharon Lerner, After 10 Long Years, American Women May Finally Get the Abortion
Pill - With Restrictions that Could Obliterate All it Has to Offer. RU Pissed Off Yet?,
available at www.villagevoice.com/issues/0035/lerner.php (Aug. 30 - Sept. 5, 2000) (last
visited Mar. 1, 2002).
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Clinical trials of RU-486 actually began in the United States in
1983 at the University of Southern California. 42  Faced with a
possible backlash from American anti-abortion activists, however,
the original developer of the drug, Roussel Uclafs parent company
Hoechst AG stated that it did not intend to "market or distribute
RU486 outside of France."43 Additionally, the drug was put on an
import alert, banning importation of the drug for personal use.44
Finally, in May of 1994, Roussel Uclaf assigned its U.S. patent
rights for RU 486 to the Population Council, a not-for-profit group,
that began clinical trials involving American women.45 Work
towards approval of the drug continued to encounter difficulties.46
Pressure from anti-abortion activists continued to build, and in
1997, the Hungarian company that had originally agreed to
manufacture the drug for U.S. markets backed out.4 7 Subsequently,
it was decided that Danco Laboratories would be formed for the
purposes of marketing and distributing the drug and that actual
manufacturers of the drugs would be kept secret.4"
Mifepristone was finally approved by the FDA on September
28, 2000.49
CURRENT LEGAL STANDARDS
Background
"It is settled now ... that the Constitution places limits on a
State's right to interfere with a person's most basic decisions about
family and parenthood."5"
The Supreme Court began its recognition of reproductive rights
in 1965."' In Griswold v. Connecticut, the Court first recognized a
42. Chronology, supra note 39.
43. Id.
44. Id.
45. Id.
46. Id.
47. Lerner, supra note 41.
48. Id.
49. Id. It is interesting to note that Mifeprex was approved under a section of FDA
regulatory statute that is usually reserved for the approval of lifesaving drugs. A true "fast
track" section, it is usually reserved for drugs that are going to be used to treat severely life-
threatening illnesses. Questions, therefore, arise as to whether the approval of the drug can
therefore be challenged or if it must be approved under a more appropriate section, and if it
required reapproval, would the drug receive it under the new administration.
50. Planned Parenthood v. Casey, 505 U.S. 833, 849 (1992).
51. Griswold v. Connecticut, 381 U.S. 479, 479 (1965).
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constitutional right to use contraceptives.52 In Griswold, the Court
struck down a Connecticut statute prohibiting the use of "any drug,
medicinal article or instrument for the purpose of preventing
conception."53 The Court recognized that, implicit in the Constitu-
tion are values whose "existence is necessary in making the express
guarantees fully meaningful."54 The Court found privacy to be one
such value.55 The Court then found that the marriage relationship
was fit within a "zone of privacy,"" and any law that violated this
right and sought "to achieve its goals by means having maximum
destructive impact upon" a protected relationship must be
unconstitutional.57
In 1972, this right of privacy was extended to unmarried people
in Eisenstadt v. Bairde.8 In that case the Court relied upon the
Equal Protection Clause of the Fourteenth Amendment when it
held a Massachusetts statute unconstitutional.59 The statute
banned the distribution of contraceptives to unmarried people, but
allowed married couples to obtain them through distribution by
prescription."° The Court stated, "If the right to privacy means
anything, it is the right of the individual, married or single, to be
free from unwarranted governmental intrusion into matters so
fundamentally affecting a person as the decision whether to bear or
beget a child."6
Finally, in Carey v. Population Services,6 2 the Court held that
a state's regulation of contraception will be scrutinized under a
strict scrutiny test and that any regulation "may be justified only
by a 'compelling state interest'... and ... must be narrowly drawn to
express only the legitimate state interests at stake."63 Thus, Carey
created a fundamental right to use contraception that remains
today.64
52. Id. (holding that married persons have a right to marital privacy, including a right
to use contraception).
53. Id. at 480.
54. Id. at 483.
55. Id. at 485.
56. Id. at 485.
57. Griswold v. Connecticut, 381 U.S. 479, 485 (1965).
58. 405 U.S. 438 (1972).
59. Id. at 443.
60. Id.
61. Id. at 453.
62. 431 U.S. 678 (1977).
63. Id. at 688 (quoting Roe v. Wade, 410 U.S. 113, 155 (1973)).
64. Id.
2002] 449
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Abortion Law
This initial recognition of a right of privacy involving
reproduction and conception eventually led to a natural expansion
of the doctrine to cover a woman's right to an abortion.6" Under
current legal standards, a woman has a constitutional right to have
an abortion, a right that was first recognized in Roe v. Wade.66 In
1992, the Court modified its holding in Roe,67 but maintained steady
in its finding of a woman's constitutional right to abortion.6"
In its 1992 decision, the Court likened a woman's right to an
abortion to the right to contraceptives, but also spent a great deal
of time distinguishing the two rights.69 "It should be recognized,
moreover, that in some critical respects the abortion decision is of
the same character as the decision to use contraception, to which
Griswold v. Connecticut, Eisenstadt v. Baird, and Carey v.
Population Services International afford constitutional protection." °
The Court, however, distinguished abortion from contraception
stating that abortion is a unique right."' It recognized that the
state has a stronger interest in regulation of abortion than it does
regarding issues of contraception.72
In Casey, the Court abandoned the trimester test developed in
Roe, 3 where the state had a varied interest in the regulation of
abortion depending on the length of the pregnancy, and the first
trimester of pregnancy was left beyond the control of any state
interference whatsoever.74 Instead, the Court developed a stan-
dard in.Casey that looked to the viability of the fetus to determine
the validity of state interest and the amount of state intrusion into
a woman's liberty right that would be allowed v5 Under this
65. Roe v. Wade, 410 U.S. 113 (1973).
66. Id.
67. It is interesting to note that under the Court's decision in Roe, the use of RU-486
could not be regulated as a procedure because the FDA has only approved it for use within
the first forty-nine days or less, counting from the beginning of the last menstrual period.
Under the Roe trimester test, where government regulation on abortion was not allowed so
long as the abortion procedure took place within the first trimester, the RU-486 abortion
could not be regulated. As discussed in the third section of this Note, however, regulation
of the drug is a possibility even under the Roe trimester test. See infra notes 82-94 and
accompanying text.
68. Planned Parenthood v. Casey, 505 U.S. 833, 833-34 (1992).
69. Id. at 849-53.
70. Id. at 852.
71. Id.
72. Id.
73. Roe v. Wade, 410 U.S. 113, 113 (1973).
74. Id. at 114.
75. Casey, 505 U.S. at 879.
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standard post-viability abortions can be prohibited except "where
it is necessary, in appropriate medical judgment, for the
preservation of the life or health of the mother."
76
On the other hand, pre-viability abortions may not be
prohibited outright.7' Regulation of such abortions is allowed
provided that such regulation is rationally related to the state's
interests,78 and not unduly burdensome on a woman's ability to
obtain an abortion. 79 A regulation related to a state's interest is not
unconstitutional if it simply has "the incidental effect of making it
more difficult or more expensive to procure an abortion." ° If a
woman does not abort before viability, it is assumed that she "has
consented to the State's intervention on behalf of the developing
child."8 '
THE DRUG AND THE LAW
According to the National Abortion and Reproductive Rights
Action League (NARAL), in 2000 439 bills aimed at restricting a
woman's access to abortion were introduced in state legislatures.82
Of these 439 bills, seventy were passed in thirty-four states.8 3 As
evidenced by the pressure exerted by anti-abortion advocates in
preventing the introduction of RU-486 into the United States'
market, there will be legislative action to restrict access to the now-
approved drug.'
Current Statutes - Do They Cover Medical Abortion?
"Having failed to prevent the federal government from
approving the abortion pill RU-486, anti-abortion advocates
76. Id. (quoting Roe, 410 U.S. at 164-65).
77. Id. at 878-79.
78. Generally, these interests include the protection of the health of the mother or an
interest in the potential life of the fetus. Id.
79. Id. at 877-89 (stating that a state regulation is overly burdensome if it "has the
purpose or effect of placing a substantial obstacle in the path of a woman seeking an abortion
of a nonviable fetus'). Id. at 877.
80. Id. at 874. Parental notification periods that contained judicial bypass clauses,
waiting periods, and state encouragement to choose childbirth were all held by the Court to
fulfill the necessary requirements as both rationally related to a state's interest and not
unduly burdensome. Id. at 879-87.
81. Id. at 870.
82. William Claiborne, Abortion Foes Want States to Curb RU-486, WASH. POST, Oct. 5,
2000, at Al.
83. Id.
84. See supra notes 36-49 and accompanying text.
2002]
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nationwide are now mobilizing to restrict its use through new state
laws."" Anti-abortion activists have already indicated "they will
seek to have bills introduced or existing abortion control laws
amended to at least restrict distribution of the drug or impede
women's access to it."86
In some cases, existing abortion laws already cover the
possibility of drug-induced termination of pregnancies. For
instance, Arizona's Criminal Code §13-3604 defines the solicitation
of abortion as the solicitation "from any person a medicine, drug or
substance whatever,.., an operation,... with the intent thereby to
procure a miscarriage. " 7 Delaware has another drug-inclusive
statute, "Abortion' means an act committed upon or with respect to
a female, whether by another person or by the female herself,
whether directly upon her body or by the administering, taking or
prescription of drugs or in any other manner, with intent to cause
a miscarriage of such female.""8
In other states, the language in existing statutes is so broad it
might cover medical abortions without the addition of language,
including specific mention of drugs. Arkansas Code § 5-61-101
states that "[lit shall be unlawful for any person to induce another
person to have an abortion or to willingly terminate the pregnancy
of a woman known to be pregnant with the intent of causing fetal
death unless such person shall be licensed to practice medicine in
the State of Arkansas." 9
Problems arise with the possibility that laws meant to cover
surgical abortions are strictly interpreted to also cover medial
abortions.90 Those staunchly opposed to the drug have suggested
using statutes in some states that require a physician or pathologist
to examine fetal tissue after an abortion.9 These opponents hope
to dissuade women from using the drug by requiring them to collect
all products of their medical "drug-induced miscarriages" and take
them to their doctor for examination.92 Such requirements would
85. Claiborne, supra note 82.
86. Id.
87. ARIZ. REV. STAT. ANN. § 13-3604 (West 1999).
88. DEL. CODE ANN. tit. 11, § 651 (1999). Other states that have similar laws that use
specific language to include drug-induced terminations include (non-exhaustive list):
Alabama, Georgia, Illinois, New Mexico, North Carolina, Tennessee and the District of
Columbia. ALA. CODE § 13A-13-7 (2000); GA. CODE ANN. § 16-12-140 (2000); 720 ILL. COMP.
STAT. 510/2 (West 2000); N.M. STAT. ANN. §30-5-3 (Michie 1978); N.C. GEN. STAT. § 14-44
(2000); TENN. CODE ANN. § 39-15-201 (2000); D.C. CODE ANN. § 22-201 (1981).
89. ARK. CODE ANN. § 5-61-101 (Michie 1987).
90. Claiborne, supra note 82.
91. Id.
92. Id.
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likely render the drug virtually useless, or at a minimum severely
curtail its use.
Some of the other proposed statutes do not act to curtail the
drug's use by such drastic means, but instead propose restrictions
on its availability.93 These proposed statutes would demand that
physicians who prescribe the drug to meet certain standards and
requirements.94
Federal Proposal - The Coburn-Hutchinson Bill
On October 4, 2000, a week after the FDA gave its final
approval for the use of Mifepristone in medical abortions,
Representative Tom Coburn (R - Oklahoma) and Senator Tim
Hutchinson (R - Arkansas) introduced legislation in Congress.9"
This legislation would require that doctors who prescribed and
administered Mifeprex be able to perform surgical abortions, thus
limiting the use of the drug to abortion clinics and thereby
defeating the pro-choice lobby's goal of expanding abortion access
beyond the clinical setting.96
Drug Regulation - The States and the FDA
State restrictions on access to Mifepristone will be limited to
restrictions on possible providers and other access related issues."
In addition to the prohibition of an outright ban on abortion
resulting from the Supreme Court's ruling in Casey,98 states lack
the authority to override federal FDA administrative rulings.99 An
outright prohibition on sale of the drug would constitute a
preemption of federal authority that has never been upheld in the
food and drug arena. 0 When questioned, FDA officials stated that
they knew of no instances in which states have successfully
overruled an agency decision approving or disapproving a drug.10 '
93. Id.
94. Id.
95. David E. Rovella, Abortion Pill Fight Shifts to the Hill, NAT'L REV. L.J., Oct. 16,2000,
atA4.
96. Id.
97. Id.
98. 505 U.S. at 852.
99. Rovella, supra note 95.
100. Id.
101. Claiborne, supra note 82.
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Experts have suggested, however, that there may be a way
around the FDA approval."°2 The FDA approved the use of
Mifepristone; the follow up drug, Misoprostol, was previously
approved by the FDA, but for the purpose of preventing ulcers.'1 3
Under current law, doctors can prescribe drugs for uses other
than those listed on the labels, in other words, for uses other than
those for which the drug has been specifically approved. 10 4 Because
the FDA has not actually approved a drug for an "off-label" use,
however, states can impose strict limitations on a drug's off-label
use." 5 For instance, many states had an outright ban on the sale
of fen-phen.' °6 This was allowed because the combination of the
therapy's components, fenfluramine and pnenolamine, was not
specifically approved by the FDA. 7 Some argue that this sets
precedent for a ban on the Mifepristone and Misoprostol
combination of drugs.' The argument is shaky, however, because
all of the pre-approval testing of Mifeprex was performed in
conjunction with Misoprostol.'1 9 Therefore, it can be said that the
approval of Mifepristone for the specific use in medical abortions
implicitly implies approval of Misoprostol for use with it."0
Ultimately, it seems that states can do little to create an outright
ban the sale of Mifeprex."
102. Charles Ornstein, Abortion Foes Shift Focus to States to Limit Pill, ARIZ. REPUBLIC,
Oct. 8, 2000, at J1.
103. See Letter from Searle to Healthcare Provider (Aug. 23, 2000), available at
http://www.fda.gov (last visited Nov. 1, 2000).
104. Off-label use is described as the prescription of a drug for a use, or in a manner not
authorized by the FDA, basically, when the actual use varies from that described on the FDA
approved package insert. Off-label use applies to non-FDA approved use, dose variation, and
use on a population, such as children, for which the drug has not been approved. See
generally Veronica Henry, Off-Label Prescribing: Legal Implications, 20 J. LEG. MED. 365
(1999) (discussion off-label drug use and legal implications); Steven R. Salbu, Off-Label Use,
Prescription, and Marketing of FDA-Approved Drugs: An Assesment of Legislative and
Regulatory Policy, 51 FLA. L. REV. 181 (1999) (describing off-label use and policy).
105. Id.
106. Id. Fen-phen was eventually taken offthe market in 1997 at the FDA's urging after
it was linked to heart-valve damaging users of the combination drug.
107. See Ornstein, supra note 102.
108. See id.
109. Karen Lee, Sensitive Benefit Issues Attend RU-486 Approval, EMPLOYEE BENEFIT
NEWS, Dec. 1, 2000. Searle is a division of drug conglomerate Pharmacia Corporation that
manufactures Misoprestol. The company did not initially approve of the drug's use in
terminating pregnancies and has gone so far as to advise doctors not to use the drug for
medical abortions. Id. Recently, however, Searle has retracted this warning. Id.
110. Id.
111. See Ornstein, supra note 102.
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Contraceptive or Abortifacient - A Special Problem
In her piece, RU 486 Examined: Impact of a New Technology on
an Old Controversy,"2 Gwendolyn Prothro examined the unique
aspects of RU-486's available uses as a contraceptive, a "morning
after pill", and an abortifacient."'
Physiologically, the RU 486 technology "blurs the
distinction between contraception and abortion" because it
operates before fertilization, in the "grey" period between
fertilization and implantation, and after implantation. RU 486's
range of effectiveness suggests that there is not a bright-line
distinction between preventing pregnancy and terminating it in
its early stages."
4
Her argument is that because RU-486 cannot be classified as
only a contraceptive or abortifacient, it blurs the semi-bright line
drawn by the Supreme Court and stated clearly in Casey." 5 This
argument, that RU 486 changes the dynamic between contraception
and abortion by making them "points on a continuum" is well
framed by her question, "is the use of RU 486 one day after
intercourse so clearly different from its use three, five, or ten days
later?""16
Under the current legal framework, a woman who takes RU-
486 as a contraceptive is covered by Griswold... and its progeny,
and is free to act without state interference."' A woman who takes
RU-486 in her eighth week of pregnancy will probably be subject to
Casey,"9 and will have to comply with any state regulations
limiting her actions. 2 °
Because of these unique, flexible qualities, the courts will have
to face certain questions that have fallen by the wayside and draw
certain lines that they have avoided in the past. Courts will have
to determine the standard to be applied to the post-fertilization and
112. Gwendolyn Prothro, RU 486 Examined: Impact of a New Technology on an Old
Controversy, 30 U. MICH. J. L. REF. 715 (1997).
113. Id.
114. Id. at 732 (quoting David Savage & Karen Tumulty, Behind the Scenes Battle Rages
over "Abortion Pill," L.A. TIMES, May 14, 1989, at 1).
115. Id. at 733.
116. Id. (quoting Brief of Amici Curiae 274 Organizations in Support of Roe v. Wade on
Behalf of Appellees, at 8 n. 12).
117. Griswold v. Connecticut, 381 U.S. 479 (1965).
118. Id. at 485; see also supra notes 64-81 and accompanying text.
119. 505 U.S. 833 (1992).
120. Prothro, supra note 112, at 733; see also Casey, 505 U.S. at 849-53.
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pre-implantation time periods, the current "grey" period that has,
up to now, been left without specific guidelines.121 This erosion of
the bright line between contraception and abortion will inevitably
broaden and deepen the abortion debate. Although RU-486
certainly strengthens the argument that a unified continuum
approach should be taken to abortion control, where the courts will
fall on this issue is yet to be seen. 2'
CONCLUSION
"What's significant about RU-486 is that it doesn't change the
legal dynamic.... It changes the real world dynamic.... "123 Whether
this is true remains to be seen.
With the approval of Mifeprex by the FDA, women in the U.S.
gained access to a relatively safe and effective (the two very things
required for FDA approval) alternative to the invasive procedure of
a surgical abortion. Questions remain, however. It is possible that
this drug will never live up to its potential. Will states be able to
effectively render the pill useless, legislating away many of its
benefits, including increased privacy and accessibility for women
seeking abortions? Certainly this is a possibility; however, it does
seem unlikely that states would be able completely to prevent
access to the drug by banning the drug completely.
Although the states cannot effectively overrule FDA approval,
they may be able to legislate distribution requirements. (Will the
FDA be able to fight off attacks on its approval through
"supremacy" arguments?) Legislation on a local level resembling
the Coburn-Hutchinson bill could take from the drug one of its main
assets: the accessibility factor. If the drug is only being distributed
where surgical abortions are being performed, the increased privacy
and accessibility are taken away.
Existing statutory language in many states already cover the
use of drugs to induce pregnancy termination. Will other states
follow? Certainly states are moving very quickly to legislate access
to this drug, and there are major political forces pulling in both
121. Prothro, supra note 112, at 735. This could very well be problematic, as the time of
implantation varies, sometimes by days, and cannot be predicted with exact precision.
Additionally, in order to determine whether implantation has occurred, extremely private
information would need to be ascertained.
122. Id. at 740.
123. Rovella, supra note 95 (quoting Professor Jonathan Entin, Case Western Reserve
University School of Law).
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directions. Although states will legislate, it remains to be seen how
they will legislate and how this legislation will be received.
Any new legislation will likely lead to litigation. The
mutability of RU-486 in its use across the "privacy" spectrum will
bring up issues that will require the courts to revisit the lines that
have been drawn and, if nothing else, define the "grey area" that
currently exists between contraception and abortion.
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